These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 6745081)

  • 1. Population pharmacokinetic data and parameter estimation based on their first two statistical moments.
    Beal SL
    Drug Metab Rev; 1984; 15(1-2):173-93. PubMed ID: 6745081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm.
    Koloskoff K; Benito S; Chambon L; Dayan F; Marquet P; Jacqz-Aigrain E; Woillard JB
    Eur J Clin Pharmacol; 2024 Jan; 80(1):83-92. PubMed ID: 37897528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.
    Zhang Y; Kuchimanchi M; Zhu M; Doshi S; Hoang T; Kasichayanula S
    Br J Clin Pharmacol; 2017 May; 83(5):1048-1055. PubMed ID: 27966237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.
    Kwak MS; Yu SJ; Yoon JH; Lee SH; Lee SM; Lee JH; Kim YJ; Lee HS; Kim CY
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2037-45. PubMed ID: 25989942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition.
    Yu SJ; Yoon JH; Yang JI; Cho EJ; Kwak MS; Jang ES; Lee JH; Kim YJ; Lee HS; Kim CY
    J Bioenerg Biomembr; 2012 Feb; 44(1):101-15. PubMed ID: 22350012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems engineering medicine: engineering the inflammation response to infectious and traumatic challenges.
    Parker RS; Clermont G
    J R Soc Interface; 2010 Jul; 7(48):989-1013. PubMed ID: 20147315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel Blocker.
    Fliss G; Staab A; Tillmann C; Trommeshauser D; Schaefer HG; Kloft C
    Pharm Res; 2008 Feb; 25(2):359-68. PubMed ID: 17587152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple absorption model for dose-escalating studies.
    Källén A
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):251-61. PubMed ID: 17285362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twitch potentiation influences the time course of twitch depression in muscle relaxant studies: a pharmacokinetic-pharmacodynamic explanation.
    Eleveld DJ; Proost JH; Wierda JM
    J Pharmacokinet Pharmacodyn; 2006 Dec; 33(6):795-806. PubMed ID: 17053983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of type I error rates when modeling ordered categorical data in NONMEM.
    Wählby U; Matolcsi K; Karlsson MO; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Feb; 31(1):61-74. PubMed ID: 15346852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug disposition analysis: a comparison between budesonide and fluticasone.
    Källén A; Thorsson L
    J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):239-56. PubMed ID: 14650373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of type I error rates for the statistical sub-model in NONMEM.
    Wählby U; Bouw MR; Jonsson EN; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):251-69. PubMed ID: 12449498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of actual significance levels for covariate effects in NONMEM.
    Wählby U; Jonsson EN; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):231-52. PubMed ID: 11468939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis.
    Pfister M; Schaedeli F; Frey FJ; Uehlinger DE
    Br J Clin Pharmacol; 1999 Jun; 47(6):645-51. PubMed ID: 10383542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Software for population pharmacokinetics and pharmacodynamics.
    Aarons L
    Clin Pharmacokinet; 1999 Apr; 36(4):255-64. PubMed ID: 10320948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.
    Karlsson MO; Jonsson EN; Wiltse CG; Wade JR
    J Pharmacokinet Biopharm; 1998 Apr; 26(2):207-46. PubMed ID: 9795882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated covariate model building within NONMEM.
    Jonsson EN; Karlsson MO
    Pharm Res; 1998 Sep; 15(9):1463-8. PubMed ID: 9755901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.
    Jelliffe RW; Schumitzky A; Bayard D; Milman M; Van Guilder M; Wang X; Jiang F; Barbaut X; Maire P
    Clin Pharmacokinet; 1998 Jan; 34(1):57-77. PubMed ID: 9474473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nonparametric subject-specific population method for deconvolution: II. External validation.
    Fattinger KE; Verotta D
    J Pharmacokinet Biopharm; 1995 Dec; 23(6):611-34. PubMed ID: 8733949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.